News for Takeda Pharmaceutical Company Limited (TAKN.MX)

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Protagonist Therapeutics, Inc. (PTGX) and Takeda Pharmaceutical Company Limited (TAK) Monday announced positive topline results from the Phase 3 VERIFY study of rusfertide in Patients with Polycythemia Vera, a type of blood cancer.

Protagonist Therapeutics, Inc. (”œProtagonist”) ([url="]NASDAQ:PTGX[/url]) and Takeda ([url="]TSE:4502/NYSE:TAK[/url]) today announced positive topline resu

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...

We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ETCompany ParticipantsChristopher O’Reilly - Head,...

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year suc…

Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER) …

/PRNewswire-PRWeb/ -- The International Society of Pharmaceutical Engineering (ISPE) has announced the 2025 Facility of the Year submission finalists. Each of...

PR NewswireSAN DIEGO, Jan. 27, 2025 - Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going to take a look at where Wave Life Sciences Ltd.

Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. (

Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option.

Takeda [url="](TSE:4502/NYSE:TAK)[/url] today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globu

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in…

Takeda ([url="]TSE:4502/NYSE:TAK[/url]) willhost an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the compa

Six Late-Stage Programs with Peak Revenue Potential of $10B – $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025 for Oveporexton (T…

Takeda ([url="]TSE:4502/NYSE:TAK[/url]) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS)

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now.